54 related articles for article (PubMed ID: 19649976)
1. The role of corticotropin-releasing factor and its receptors in the central nervous system.
Heinrichs SC
Curr Opin Drug Discov Devel; 1999 Sep; 2(5):491-6. PubMed ID: 19649976
[TBL] [Abstract][Full Text] [Related]
2. Corticotropin-releasing factor antagonists, binding-protein and receptors: implications for central nervous system disorders.
Heinrichs SC; De Souza EB
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Dec; 13(4):541-54. PubMed ID: 10903813
[TBL] [Abstract][Full Text] [Related]
3. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation.
Heinrichs SC; Koob GF
J Pharmacol Exp Ther; 2004 Nov; 311(2):427-40. PubMed ID: 15297468
[TBL] [Abstract][Full Text] [Related]
4. Central hyperventilatory action of the stress-related neurohormonal peptides, corticotropin-releasing factor and urotensin-I in the trout Oncorhynchus mykiss.
Le Mével JC; Lancien F; Mimassi N; Conlon JM
Gen Comp Endocrinol; 2009 Oct; 164(1):51-60. PubMed ID: 19341734
[TBL] [Abstract][Full Text] [Related]
5. Ontogeny of the corticotropin-releasing factor system in zebrafish.
Alderman SL; Bernier NJ
Gen Comp Endocrinol; 2009 Oct; 164(1):61-9. PubMed ID: 19366623
[TBL] [Abstract][Full Text] [Related]
6. In vivo evidence for ligand-specific receptor activation in the central CRF system, as measured by local cerebral glucose utilization.
Warnock G; Moechars D; Langlois X; Steckler T
Peptides; 2009 May; 30(5):947-54. PubMed ID: 19428773
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system.
Sutton SW; Shelton J; Smith C; Williams J; Yun S; Motley T; Kuei C; Bonaventure P; Gundlach A; Liu C; Lovenberg T
Ann N Y Acad Sci; 2009 Apr; 1160():242-9. PubMed ID: 19416196
[TBL] [Abstract][Full Text] [Related]
8. Nicotine suppresses energy storage through activation of sympathetic outflow to brown adipose tissue via corticotropin-releasing factor type 1 receptor.
Mano-Otagiri A; Iwasaki-Sekino A; Ohata H; Arai K; Shibasaki T
Neurosci Lett; 2009 May; 455(1):26-9. PubMed ID: 19429100
[TBL] [Abstract][Full Text] [Related]
9. Gene-environment interactions resulting in risk alcohol drinking behaviour are mediated by CRF and CRF1.
Clarke TK; Schumann G
Pharmacol Biochem Behav; 2009 Sep; 93(3):230-6. PubMed ID: 19409922
[TBL] [Abstract][Full Text] [Related]
10. Roles of calcitonin gene-related peptide and its receptors in pain-related behavioral responses in the central nervous system.
Yu LC; Hou JF; Fu FH; Zhang YX
Neurosci Biobehav Rev; 2009 Sep; 33(8):1185-91. PubMed ID: 19747596
[TBL] [Abstract][Full Text] [Related]
11. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Hartz RA; Ahuja VT; Zhuo X; Mattson RJ; Denhart DJ; Deskus JA; Vrudhula VM; Pan S; Ditta JL; Shu YZ; Grace JE; Lentz KA; Lelas S; Li YW; Molski TF; Krishnananthan S; Wong H; Qian-Cutrone J; Schartman R; Denton R; Lodge NJ; Zaczek R; Macor JE; Bronson JJ
J Med Chem; 2009 Dec; 52(23):7653-68. PubMed ID: 19954247
[TBL] [Abstract][Full Text] [Related]
12. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436
[TBL] [Abstract][Full Text] [Related]
13. [Neuropeptide Y--structure, receptors, effect and its place in psychiatry].
Bobińska K; Szemraj J; Pietras T; Zboralski K; Gałecki P
Psychiatr Pol; 2008; 42(6):889-901. PubMed ID: 19441666
[TBL] [Abstract][Full Text] [Related]
14. Opioids and sensory nerves.
Stein C; Zöllner C
Handb Exp Pharmacol; 2009; (194):495-518. PubMed ID: 19655116
[TBL] [Abstract][Full Text] [Related]
15. [Stress: a neurobiological perspective].
de Kloet ER
Tijdschr Psychiatr; 2009; 51(8):541-50. PubMed ID: 19658066
[TBL] [Abstract][Full Text] [Related]
16. CRH signaling. Molecular specificity for drug targeting in the CNS.
Refojo D; Holsboer F
Ann N Y Acad Sci; 2009 Oct; 1179():106-19. PubMed ID: 19906235
[TBL] [Abstract][Full Text] [Related]
17. The endocrine control of salt balance in insects.
Coast G
Gen Comp Endocrinol; 2007; 152(2-3):332-8. PubMed ID: 17400222
[TBL] [Abstract][Full Text] [Related]
18. Membrane cholesterol depletion enhances ligand binding function of human serotonin1A receptors in neuronal cells.
Prasad R; Paila YD; Chattopadhyay A
Biochem Biophys Res Commun; 2009 Dec; 390(1):93-6. PubMed ID: 19781522
[TBL] [Abstract][Full Text] [Related]
19. Bivalent argininamide-type neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation.
Keller M; Teng S; Bernhardt G; Buschauer A
ChemMedChem; 2009 Oct; 4(10):1733-45. PubMed ID: 19672917
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoid system: An overview of its potential in current medical practice.
Mouslech Z; Valla V
Neuro Endocrinol Lett; 2009; 30(2):153-79. PubMed ID: 19675519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
